• Dlin-MC3-DMA: Practical RNA LNP Workflow

  2026-10-01

  Dlin-MC3-DMA provides a practical benchmark for building pH-responsive LNPs for hepatic gene silencing, siRNA delivery, and mRNA expression studies. This guide translates its solvent handling, formulation logic, and troubleshooting needs into an experimental workflow while clearly separating established MC3 use from emerging cancer-immunotherapy designs.

• PreScission Protease for Condensate-Ready Proteins

  2026-10-01

  PreScission Protease enables precise HRV 3C protease-mediated tag removal before protein condensate assays. This article explains how cleavage-site design, low-temperature handling, and orthogonal controls can improve interpretation of Keap1 nuclear condensate experiments.

• Low-Dose Orlistat Enhances Oxaliplatin in CRC

  2026-09-30

  The reference study reports that low-dose orlistat sensitizes colorectal cancer models to Oxaliplatin, producing synergistic cytotoxicity and apoptosis in cell and patient-derived xenograft systems. Its combination of computational synergy analysis, PDX validation, and an apoptosis-focused gene array provides a practical framework for investigating chemosensitization while highlighting the need for further clinical validation.

• Bradykinin BA5201: Reliable Assay Workflows

  2026-09-30

  This scenario-driven guide explains how Bradykinin, SKU BA5201, can be incorporated into cell viability, proliferation, cytotoxicity, and vascular signaling workflows without confusing mechanistic effects with assay artifacts. It covers product handling, experimental controls, molar calculations, interpretation, and practical vendor-selection criteria.

• Octyl-α-ketoglutarate in HIF-1α Assays

  2026-09-29

  Octyl-α-ketoglutarate provides a cell-permeable way to interrogate α-ketoglutarate control of HIF-1α regulation. This guide translates IDH2–α-KG biology into practical assay designs that distinguish prolyl hydroxylase activity from broader metabolic effects.

• Pam3CSK4 in Neuro-Immune Inflammation Assays

  2026-09-29

  Pam3CSK4 is a defined TLR1/2 agonist for dissecting immune cell activation, macrophage nitric oxide production, and inflammatory signaling. This article explains how to use it as a standardized immune challenge when investigating neural regulation of inflammation without confusing correlation with mechanism.

• 5-Methyl-CTP: From RNA Chemistry to Vaccine Assays

  2026-09-28

  Explore how 5-Methyl-CTP can connect transcript chemistry with delivery-focused mRNA vaccine assays. This article moves beyond basic stability claims to define practical controls, analytical readouts, and limitations for mRNA drug development.

• Lysosomal Exocytosis in MPS IVA Cartilage Pathology

  2026-09-28

  A zebrafish model of mucopolysaccharidosis type IVA links enhanced lysosomal exocytosis with reduced cathepsin activity, weaker TGFβ and BMP signaling, and altered glycosaminoglycan abundance in developing cartilage. The findings extend disease mechanisms beyond substrate storage, while leaving open whether exocytosis is a cause, consequence, or amplifier of cartilage pathology.

• β-Galactosidase Reporter Assay Kit for Promoters

  2026-09-27

  A β-Galactosidase Reporter Assay Kit can turn promoter activity into a measurable enzyme signal, but the result reflects more than transcription alone. This guide explains how to interpret reporter data in light of a 2026 study designing modular promoters for Escherichia coli and Saccharomyces cerevisiae.

• From HATU Coupling to Selective IRAP Inhibitors

  2026-09-26

  How HATU-enabled bond construction can support the synthesis of structurally informed inhibitor series—and how recent IRAP research illustrates the translational value and limits of that connection.

• CAY10499: inhibitor of human hormone sensitive lipase

  2026-09-25

  Learn how to use CAY10499 (SKU B7841) when lipid metabolism complicates cell viability, proliferation, or cytotoxicity experiments. This scenario-based guide explains its reported enzyme potencies, practical handling, assay controls, and the limits of extrapolating biochemical results to cells.

• Isoprinosine: Evidence and Research Workflow

  2026-09-25

  Isoprinosine, also called inosine pranobex, is described as an immunomodulatory compound with reported antiviral activity and clinical evidence for selected acute respiratory viral infections. Its evidence should be kept separate from new HSV-1 nuclear-egress findings on CLCC1, which identify a host-cell process but do not test Isoprinosine.

• Angiotensin I: Practical RAS Assay Workflows

  2026-09-24

  Use Angiotensin I to model renin–angiotensin system activity, measure ACE-mediated conversion, and build focused antihypertensive screening assays. This guide pairs practical peptide-handling and assay controls with a careful interpretation of a fluorescence-interference study—without treating its bioaerosol results as validation for cardiovascular experiments.

• Sulfo-NHS-Biotin: Choosing Labeling for Function

  2026-09-24

  Sulfo-NHS-Biotin offers a practical route to covalent protein capture, but labeling chemistry can shape assay function as much as detection. This guide compares random amine labeling with site-specific biotinylation and shows how to choose a strategy for interpretable protein assays.

• LY2886721: A BACE Inhibitor Workflow for AD Research

  2026-09-23

  LY2886721 supports dose-response studies that connect BACE1 enzyme inhibition and amyloid beta reduction with functional neuronal readouts. This workflow emphasizes measuring Aβ alongside synaptic transmission, so researchers can distinguish moderate pathway modulation from stronger inhibition that may affect neuronal function.

527 records 1/36 page Next 12345 下5页 Last page